Cancer Therapy

You have full text access to this OnlineOpen article

The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies

  1. Wai M. Liu†,*,
  2. Andrew M. Gravett,
  3. Angus G. Dalgleish

Article first published online: 28 NOV 2010

DOI: 10.1002/ijc.25707

Issue

International Journal of Cancer

International Journal of Cancer

Volume 128, Issue 6, pages 1471–1480, 15 March 2011

Additional Information

How to Cite

Liu, W. M., Gravett, A. M. and Dalgleish, A. G. (2011), The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int. J. Cancer, 128: 1471–1480. doi: 10.1002/ijc.25707

Author Information

  1. Department of Oncology, Division of Clinical Sciences, St George's, University of London, United Kingdom

  1. †

    Tel.: +44-(0)20-8725-5037

*Department of Oncology, Division of Clinical Sciences, St George's, University of London, 2nd Floor, Jenner Wing, London SW17 0RE, United Kingdom

Publication History

  1. Issue published online: 28 JAN 2011
  2. Article first published online: 28 NOV 2010
  3. Accepted manuscript online: 30 SEP 2010 12:50PM EST
  4. Manuscript Accepted: 17 SEP 2010
  5. Manuscript Received: 26 JUL 2010

Funded by

  • Celgene Corp and Cancer Vaccine Institute

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (922K)

References

  • 1
    Li GQ, Arnold K, Guo XB, Jian HX, Fu LC. Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. Lancet 1984; 2: 1360–1.
  • 2
    Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 2008; 29: 520–7.
  • 3
    Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32: 1655–60.
  • 4
    Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 2006; 36: 1427–41.
  • 5
    Guidelines for the treatment of malaria. Geneva: World Health Organisation, 2006. (WHO/HTM/MAL/2006.1108). http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf.
  • 6
    Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767–73.
  • 7
    Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007; 2: e693.
  • 8
    Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13: 353–61.
  • 9
    Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L, Sun ZX. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer 2007; 121: 1360–5.
    Direct Link:
  • 10
    Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009; 20: 131–40.
  • 11
    Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010; 65: 895–902
  • 12
    Gravett A, Liu W, Krishna S, Chan WC, Haynes R, Wilson N, Dalgleish A. In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol 2010. [Epub ahead of print]
  • 13
    Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, Breitling R, Mayer B, Deubzer H, Witt O, Kreuter J, Doerr HW, Cinatl J, et al. Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol 2010; 79: 130–6.
  • 14
    Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008; 14: 5519–30.
  • 15
    Zhou HJ, Wang Z, Li A. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. Anticancer Drugs 2008; 19: 247–55.
  • 16
    Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 2006; 6: 269–78.
  • 17
    Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 2007; 47: 131–8.
  • 18
    Rasheed SA, Efferth T, Asangani IA, Allgayer H. First evidence that the anti-malarial drug Artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 2010; 127: 1475–85.
    Direct Link:
  • 19
    Li S, Xue F, Cheng Z, Yang X, Wang S, Geng F, Pan L. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int J Hematol 2009; 90: 513–21.
  • 20
    Li B, Li J, Pan X, Ding G, Cao H, Jiang W, Zheng J, Zhou H. Artesunate protects sepsis model mice challenged with Staphylococcus aureus by decreasing TNF-alpha release via inhibition TLR2 and Nod2 mRNA expressions and transcription factor NF-kappaB activation. Int Immunopharmacol 2010; 10: 344–50.
  • 21
    Liu WM. Enhancing the cytotoxic activity of novel targeted therapies—is there a role for a combinatorial approach? Curr Clin Pharmacol 2008; 3: 108–17.
  • 22
    Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G. Artesunate in the treatment of metastatic uveal melanoma—first experiences. Oncol Rep 2005; 14: 1599–603.
  • 23
    Efferth T, Ramirez T, Gebhart E, Halatsch ME. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 2004; 67: 1689–700.
  • 24
    Sieber S, Gdynia G, Roth W, Bonavida B, Efferth T. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. Int J Oncol 2009; 35: 149–58.
  • 25
    Liu WM, Scott KA, Shamash J, Joel S, Powles TB. Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma 2008; 49: 1800–9.
  • 26
    Liu WM, Lawrence AJ, Joel SP. The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cells. Eur J Cancer 2002; 38: 842–50.
  • 27
    Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 1993; 37: 1108–14.
  • 28
    Xu H, He Y, Yang X, Liang L, Zhan Z, Ye Y, Yang X, Lian F, Sun L. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology 2007; 46: 920–6.
  • 29
    Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68: 4347–51.
  • 30
    Castedo M, Coquelle A, Vitale I, Vivet S, Mouhamad S, Viaud S, Zitvogel L, Kroemer G. Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Ann N Y Acad Sci 2006; 1090: 35–49
    Direct Link:
  • 31
    Ganem NJ, Storchova Z, Pellman D. Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 2007; 17: 157–62
  • 32
    Chang DK, Ricciardiello L, Goel A, Chang CL, Boland CR. Steady-state regulation of the human DNA mismatch repair system. J Biol Chem 2000; 275: 29178.
  • 33
    Abdel-Rahman WM, Katsura K, Rens W, Gorman PA, Sheer D, Bicknell D, Bodmer WF, Arends MJ, Wyllie AH, Edwards PA Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci USA 2001; 98: 2538–43.
  • 34
    Plaschke J, Krüger S, Jeske B, Theissig F, Kreuz FR, Pistorius S, Saeger HD, Iaccarino I, Marra G, Schackert HK. Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res 2004; 64: 864–70.
  • 35
    Baatout S. Molecular basis to understand polyploidy. Hematol Cell Ther 1999; 41: 169–70.
  • 36
    Lee HO, Davidson JM, Duronio RJ. Endoreplication: polyploidy with purpose. Genes Dev 2009; 23: 2461–77.
  • 37
    Liu WM, Joel SP. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemother Pharmacol 2003; 51: 291–6.
  • 38
    Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 17: 1794–805.
  • 39
    Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G, Bellacosa A, Capitani S, Martelli AM. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234–46.
  • 40
    Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009; 10: 125–33
View Full Article (HTML) Get PDF (922K)